1. Inicio
  2. Publicaciones
  3. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Labrador J
  • Saiz-Rodríguez M
  • de Miguel D
  • de Laiglesia A
  • Rodríguez-Medina C
  • Vidriales MB
  • Pérez-Encinas M
  • Jose Sanchez-Sanchez, Maria
  • Cuello R
  • Roldán-Pérez A
  • Vives S
  • Benzo-Callejo G
  • Colorado M
  • García-Fortes M
  • Jose Sayas, Maria
  • Olivier C
  • Recio I
  • Conde-Royo D
  • Bienert-García Á
  • Vahi M
  • Munoz-Garcia, Carmen
  • Seri-Merino C
  • Tormo M
  • Vall-Llovera F
  • Foncillas MÁ

Grupos

Abstract

The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received =2 therapies for AML, 49% had received hypomethylating agents, and ECOG was =2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with increased CR/CRi. Median OS was 104 days (95% CI: 56-151). For the combination with AZA, DEC, and LDAC, median OS was 120 days, 104 days, and 69 days, respectively; p = 0.875. Treatment response and ECOG 0 influenced OS in a multivariate model. A total of 28% of patients required interruption of VEN because of toxicity. Our real-life series describes a marginal probability of CR/CRi and poor OS after VEN-based salvage. Patients included had very poor-risk features and were heavily pretreated. The small percentage of responders did not reach the median OS.

Datos de la publicación

ISSN/ISSNe:
2072-6694, 2072-6694

Cancers  MDPI

Tipo:
Article
Páginas:
-
PubMed:
35406512
Factor de Impacto:
1,349 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 27

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acute myeloid leukemia; refractory; relapsed; venetoclax

Campos de Estudio

Compartir